Shanghai Kweitec Biotechnology

Shanghai Kweitec Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics targeting protein-protein interactions (PPI). The company leverages a proprietary structure-based drug design platform to address "undruggable" targets in oncology and immunology. Its lead programs focus on the RAS/MAPK signaling pathway, including inhibitors for SHP2 and SOS1. Headquartered in Shanghai's Zhangjiang Hi-Tech Park, Kweitec is backed by prominent venture capital firms like Qiming Venture Partners and Lilly Asia Ventures. The company aims to provide next-generation precision medicines for patients with unmet medical needs, particularly in the field of solid tumors. Kweitec's approach combines advanced computational chemistry with structural biology to accelerate the drug discovery process.